ACAD
18.125
-1.235
-6.379%
AEMD
4.55
-0.35
-7.14%
APRI
1.13
-0.04
-3.42%
ARNA
1.49
-0.08
-5.10%
ATEC
0.39
-0.01
-2.50%
CNAT
1.68
-0.16
-8.70%
CRXM
0.25
0.00
0.00%
CYTX
0.138
-0.041
-22.9353%
DXCM
49.82
-12.16
-19.62%
GNMK
5.08
0.00
0.00%
HALO
7.195
-0.705
-8.924%
ILMN
133.6
-2.45
-1.80%
INNV
0.035
-0.003
-7.652%
INO
5.84
-0.17
-2.83%
ISCO
2.76
+0.36
+15.00%
ISIS
57.56
0.00
0.00%
LGND
88.16
-4.34
-4.69%
LPTN
0.15
-0.01
-6.31%
MBVX
0.515
-0.025
-4.630%
MEIP
1.21
-0.03
-2.42%
MNOV
4.199
+0.049
+1.1904%
MRTX
19.08
-1.18
-5.82%
MSTX
0.41
+0.00
+0.0244%
NBIX
32.9
-3.09
-8.59%
NUVA
40.08
-1.37
-3.31%
ONCS
1.62
-0.07
-4.14%
ONVO
1.95
-0.14
-6.70%
OREX
1.75
-0.09
-4.89%
OTIC
12.74
-1.06
-7.68%
QDEL
16.02
-0.38
-2.32%
RCPT
231.96
0.00
0.00%
RGLS
5.44
-0.5
-8.42%
RMD
57.05
-0.37
-0.64%
SCIE
0.001
0.00
-10.0000%
SPHS
1.67
-0.01
-0.60%
SRNE
4.83
-0.22
-4.36%
TROV
3.67
-0.18
-4.6779%
VICL
0.348
+0.015
+4.4484%
VOLC
18
0.00
0.00%
ZGNX
8.29
-0.2
-2.36%
ACAD
18.125
-1.235
-6.379%
AEMD
4.55
-0.35
-7.14%
APRI
1.13
-0.04
-3.42%
ARNA
1.49
-0.08
-5.10%
ATEC
0.39
-0.01
-2.50%
CNAT
1.68
-0.16
-8.70%
CRXM
0.25
0.00
0.00%
CYTX
0.138
-0.041
-22.9353%
DXCM
49.82
-12.16
-19.62%
GNMK
5.08
0.00
0.00%
HALO
7.195
-0.705
-8.924%
ILMN
133.6
-2.45
-1.80%
INNV
0.035
-0.003
-7.652%
INO
5.84
-0.17
-2.83%
ISCO
2.76
+0.36
+15.00%
ISIS
57.56
0.00
0.00%
LGND
88.16
-4.34
-4.69%
LPTN
0.15
-0.01
-6.31%
MBVX
0.515
-0.025
-4.630%
MEIP
1.21
-0.03
-2.42%
MNOV
4.199
+0.049
+1.1904%
MRTX
19.08
-1.18
-5.82%
MSTX
0.41
+0.00
+0.0244%
NBIX
32.9
-3.09
-8.59%
NUVA
40.08
-1.37
-3.31%
ONCS
1.62
-0.07
-4.14%
ONVO
1.95
-0.14
-6.70%
OREX
1.75
-0.09
-4.89%
OTIC
12.74
-1.06
-7.68%
QDEL
16.02
-0.38
-2.32%
RCPT
231.96
0.00
0.00%
RGLS
5.44
-0.5
-8.42%
RMD
57.05
-0.37
-0.64%
SCIE
0.001
0.00
-10.0000%
SPHS
1.67
-0.01
-0.60%
SRNE
4.83
-0.22
-4.36%
TROV
3.67
-0.18
-4.6779%
VICL
0.348
+0.015
+4.4484%
VOLC
18
0.00
0.00%
ZGNX
8.29
-0.2
-2.36%
Home » Archive by Category

Syndication

OncoSec to Present at Prominent Investment Conferences in February

February 3, 2016 – 4:00 am

SAN DIEGO, Feb. 3, 2016 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in February, including:

  • The 18th Annual BIO CEO & Investor Conference
  • Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
  • Biocom’s Global Life Science Partnering Conference
  • 4th Annual Sachs Cancer Bio Partnering & Investment Forum

The 18th Annual BIO CEO & Investor Conference
Punit Dhillon, President and CEO, will present a corporate overview at The 18th Annual BIO CEO & Investor Conference on February 8 at 11:00 AM ET at The Waldorf Astoria in New York City. To view to the live webcast, please access the following link at the time of the presentation: http://www.veracast.com/webcasts/bio/ceoinvestor2016/76113125724.cfm. An archived version of the webcast will be available for 90 days on OncoSec’s website: http://www.oncosec.com.

In its eighteenth year, The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Companies are able to present their company story to an audience of target investors and meet one-on-one with new and current investors, analysts, investment bankers, and other potential corporate partners. The conference also provides a platform to network with peers, investors, and potential partners attending the conference. For more information, please visit: https://www.bio.org/events/conferences/bio-ceo-investor-conference.

Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
Mr. Dhillon will present a corporate overview at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 10 at 12:30 PM ET at Convene in New York City.

The 2016 Disruptive Growth & Healthcare Conference will feature presentations from life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models. Attendees will include over 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, Source representatives, and their clients. The panels will cover a variety of topics, including regenerative medicine, immunotherapy, diagnostics, disruptive innovations, and business models. For more information, please visit: www.sourcecapitalconference.com.

Biocom’s Global Life Science Partnering Conference
Mr. Dhillon will present a corporate overview at Biocom’s Global Life Science Partnering Conference taking place February 24-25 at The Lodge at Torrey Pines in La Jolla, CA.  

Biocom’s 6th Annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. The conference will include panel discussions on relevant topics with senior industry leaders, start-up company presentations, one-on-one meetings, and numerous networking opportunities. For more information, please visit: https://www.biocom.org.

4th Annual Sachs Cancer Bio Partnering & Investment Forum
Robert H. Pierce, MD, Chief Scientific Officer, will present a corporate overview at the 4th Annual Sachs Cancer Bio Partnering & Investment Forum on February 24 at 2:40 PM ET at the New York Academy of Sciences in New York City.

The 4th Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical, and biotech to facilitate partnering and funding/investment. The conference will attract approximately 250 delegates and 30 company presentations by listed and private biotechnology companies seeking licensing and investment opportunities. The event provides a platform for one-on-one meetings and dedicated meeting facilities to make the event more productive. For more information, please visit: http://www.sachsforum.com/.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer.  ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

Contact
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

Logo – http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

SOURCE OncoSec Medical Incorporated

Time to Ease On Down the Road

February 3, 2016 – 1:00 am

It’s been a real pleasure writing my guest op-ed pieces for Xconomy for the past six years. I’ve enjoyed sharing my thoughts about a wide spectrum of biopharma topics, and appreciated the feedback I…

[[Click headline to continue reading.]]

Associate Director, Fill/Finish Manufacturing – 2nd Shift – Ajinomoto Althea, Inc. – San Diego, CA

February 2, 2016 – 11:27 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From DeviceSpace.com – 03 Feb 2016 06:27:27 GMT
– View all San Diego …

Temporary R&D Program Manager – Vertex Pharmaceuticals – San Diego, CA

February 2, 2016 – 11:05 pm

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better…
From Vertex Pharmaceuticals – 03 Feb 2016 06:05:48 GMT
– View all…

Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Production of C-Cure®

February 2, 2016 – 11:00 pm

Invetech to design and supply automated production systems for commercialization of autologous cell therapy based on Celyad’s cardiopoiesis technology platform




SAN DIEGO, Feb. 3, 2016 /PRNewswire/ — Invetech, a global leader in instrument development, custom automation and contract manufacturing, and Celyad SA, (CYAD.BR) (“Celyad”), a biopharmaceutical company focused on identification and development of specialized cell-based therapies with product candidates in oncology and cardiology, today announced that they have entered into an agreement under which Invetech will develop and supply manufacturing systems to support production needs for C-Cure®,  Celyad’s most advanced product candidate based on the cardiopoiesis technology platform. Under the terms of the agreement, Invetech will provide Celyad with a range of advanced design and manufacturing services to support development of customized manufacturing systems for commercial production of C-Cure®.

“Our feasibility study for automated manufacturing of C-Cure® delivered excellent results and provided strong support for the continued development of this promising automation platform. Importantly, this program also builds on and expands our expertise in core cell therapy development,” said Dieter Hauwaerts, vice president, operations, Celyad.

In this collaboration, the system design and production teams at Invetech will supply Celyad with a modular, readily scalable and highly automated production suite able to facilitate simultaneous processing of multiple patient-specific therapies. The manufacturing system is designed to be rapidly expandable to accommodate anticipated increases in production volume to support future global commercialization pending regulatory approvals.

“We are pleased to be supporting Celyad in the translation of their exciting C-Cure® product from clinical trials to commercial production.  Our experience with automating manual processes has enabled us to design a GMP compliant manufacturing system that meets Celyad’s need for efficient manufacturing combined with patient safety,” said Richard Grant, Global Vice President, Cell Therapy, at Invetech.  “This agreement reflects Invetech’s ability to adapt biopharmaceutical process design methodologies to address the unique demands and challenges presented by the cell therapy industry.”

About C-Cure®

C-Cure® is Celyad’s most advanced product candidate based on its cardiopoiesis platform and is being developed for heart failure indications. The Company expects to release the full clinical data set for CHART-1, its Phase III trial in Europe and Israel, in the middle of 2016. The research underlying this technology was originally conducted at Mayo Clinic by the research team of Professor André Terzic and Atta Behfar, and has been published in numerous peer-reviewed publications.  C-Cure® consists of a patient’s own cells harvested from bone marrow, treated with cardiopoietic growth factors and then re-injected into the heart. It is designed to produce new autologous heart muscle cells that behave identically to those lost as a result of infarction, without the risk of rejection. C-Cure®’s potential has been demonstrated in a multi-center randomized controlled Phase II trial conducted in Europe. Results of the C-Cure® Phase II trial were published in April 2013 in the Journal of American College of Cardiology.

About Celyad
Celyad, previously Cardio3 BioSciences, is a biopharmaceutical company focused on translating breakthrough cell-based research into innovative therapeutics to improve the outcome of severe diseases. The Company is currently developing clinical stage cell therapies in cardiology and oncology, two healthcare segments with high unmet medical needs.

About Invetech
Invetech has been creating breakthrough products and custom automation systems for more than 30 years. With experience drawn from more than 5000 projects globally, Invetech partners with global leaders in industry to deliver product design and development, contract manufacturing and custom automation services.  The company has experience in a broad range of market sectors including cell therapy production automation systems, laboratory diagnostics, point of care diagnostics, life sciences, industrial and consumer products. 

Media Contact
Bill Berry
Berry & Company Public Relations
bberry@berrypr.com
Ph +1 212.253.8881

Logo – http://photos.prnewswire.com/prnh/20160202/329042LOGO
Logo – http://photos.prnewswire.com/prnh/20160202/329043LOGO

 

SOURCE Invetech

Project Manager-Engineering – Pacira Pharmaceuticals – San Diego, CA

February 2, 2016 – 6:17 pm

8+ years of direct experience in facilities engineering, facilities operations or project engineering in commercial pharmaceutical, biotechnology or medical…
From Pacira Pharmaceuticals – 03 Feb 2016 01:17:02 GMT
– View all S…

Manager, Facilities – ADC – Ajinomoto Althea, Inc. – San Diego, CA

February 2, 2016 – 5:34 pm

Provides Facilities support to research, development, clinical and commercial biotechnology operations including bulk production and aseptic filling activities….
From Ajinomoto Althea, Inc. – 03 Feb 2016 00:34:39 GMT
– View a…

Staff Accountant (Pacific Beach)

February 2, 2016 – 5:25 pm

Function/Scope:
The Staff Accountant is responsible for collecting, processing and maintaining all records related to the accounts payable function; preparing and processing certain journal entries; reconciling certain financial data and reports; an […

Executive Assistant – Evofem – San Diego, CA

February 2, 2016 – 4:59 pm

Evofem is a San Diego-based biotechnology company founded in 2009. We have leveraged our scientific and business talent to focus on developing innovative…
From Indeed – 02 Feb 2016 23:59:58 GMT
– View all San Diego jobs

Life Science Recruiter (Sorrento Valley)

February 2, 2016 – 4:56 pm

R&D Partners is a fast growing national Life Science staffing firm focused in the areas of Scientific, Clinical Research & Engineering. We are seeking highly motivated and driven individuals to recruit professionals for the world’s top Life Science c […]